Sanofi announced that its experimental drug lunsekimig achieved primary and key secondary endpoints in two phase 2 respiratory studies targeting moderate to severe asthma and chronic rhinosinusitis with nasal polyps. The drug, designed to block two inflammatory factors, showed significant reduction in asthma exacerbations and improvement in lung function, as well as reduced nasal polyp scores. Lunsekimig was well tolerated with a favorable safety profile. However, it did not meet the primary endpoint in a separate phase 2 study for atopic dermatitis. Sanofi plans to present detailed results at upcoming medical conferences and continues clinical development in phase 2 and 3 trials.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
